Prascend Tablets is the first and only FDA-approved oral treatment for the control of clinical signs associated with Equine Cushing's Disease (Pituitary Pars Intermedia Dysfunction).
Dosage and Administration: Administer orally at a starting dose of 2 mcg/kg once daily. Dosage may be adjusted to effect, not to exceed 4 mcg/kg daily. It has been reported that pergolide tablets may cause eye irritation, an irritating smell, or headache when Prascend Tablets are split or crushed. Prescend Tablets should not be crushed due to the potential for increased human exposure and care should be taken to minimize exposure when splitting tablets.
Dosages listed below are at 2 mcg/kg to 4 mcg/kg for each weight range:
136 - 340 kg (300-749 lb) . . . 0.5 tablet to 1 tablet
341 - 567 kg (750 - 1,249 lb) . . . 1 tablet to 2 tablets
568 - 795 kg (1,250 - 1,749 lb) . . . 1.5 tablets to 3 tablets
796 - 1,022 kg (1,750 - 2,249 lb) . . . 2 tablets to 4 tablets
Tablets are scored and the calculated dosage should be provided to the nearest one-half tablet increment.
Dosage should be titrated according to individual response to therapy to achieve the lowest effective dose. Dose titration is based on improvement in clinical signs associated with Pituitary Pars Intermedia Dysfunction (PPID) and/or improvement or normalization of endocrine tests. If signs of dose intolarance develop, the dose should be decreased by half for 3 to 5 days then titrated back up in 2 mcg/kg increments every 2 weeks until the desired effect is achieved.
Do not use in horses intended for human consumption. May interfere with reproductive hormones and events in breeding, pregnant or lactating horses.
Federal law restricts this drug to use by or on the order of a licensed veterinarian
Rx Medication Sold Only To Licensed Veterinarians & Pharmacies. Current License Must Be On File Prior To Shipping.
Additional information not available for this medicine.
